Background pattern
FILSUVEZ GEL

FILSUVEZ GEL

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use FILSUVEZ GEL

Introduction

Package Leaflet: Information for the Patient

Filsuvez Gel

Birch Bark Extract

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the Package Leaflet

  1. What is Filsuvez and what is it used for
  2. What you need to know before you use Filsuvez
  3. How to use Filsuvez
  4. Possible side effects
  5. Storage of Filsuvez
  6. Contents of the pack and other information

1. What is Filsuvez and what is it used for

Filsuvez gel is a herbal medicine that contains dry extract of birch bark.

It is used for the treatment of wounds in adults and children (from 6 months of age) who suffer from a type of disease called "epidermolysis bullosa" (EB), specifically "dystrophic" (DEB) or "junctural" (JEB). This is a condition where the outer layer of the skin separates from the inner layer, making the skin very fragile and causing wounds to appear.

2. What you need to know before you use Filsuvez

Do not use Filsuvez

  • if you are allergic to birch bark or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before you start using Filsuvez.

If you have an allergic reaction, stop using Filsuvez immediatelyand go to your doctor or nurse. Signs of an allergic reaction include:

  • itching, swelling, and redness of the skin that is more severe in the area where the medicine has been applied.

Wound infection is a serious complicationthat can occur during the healing process. Possible signs of wound infection are:

  • yellow or greenish liquid (pus) coming out of the wound,
  • red, hot, swollen, or increasingly painful skin around the wound.

If you have a wound infection, you may need to stop using Filsuvezand another treatment may be necessary. Your doctor or nurse will tell you if Filsuvez treatment can be restarted once the infection has cleared up.

People with EB are more likely to develop a type of skin cancer called "squamous cell carcinoma" (SCC). If you are diagnosed with skin cancer while using Filsuvez, you should talk to your doctor or nurse and stop using Filsuvezon that part of the skin.

Filsuvez does notcontain birch pollen, so it can be used in people with a birch pollen allergy.

Avoid getting Filsuvez in your eyes. If this happens, rinse your eyes well with clean water. Contact your doctor or nurse if the discomfort continues.

Children

Do not give this medicine to children under 6 months of age.

Other medicines and Filsuvez

Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use any other medicines.

There is no information on how Filsuvez might interact with other medicines applied to the skin, taken by mouth, or injected. Do not apply other products to the wound area at the same time as applying Filsuvez. If you need to use more than one product, talk to your doctor or nurse.

Pregnancy, breastfeeding, and fertility

No studies have been done on the effects of Filsuvez in pregnant women, but since the absorption of this medicine into the body is extremely low, the risk to the fetus is negligible. Filsuvez can be used during pregnancy.

It is not known if Filsuvez passes into breast milk, but since the absorption of this medicine into the body is extremely low, the risk to the fetus is negligible. Filsuvez can be used during breastfeeding, unless the breast area is being treated.

Since the absorption of this medicine into the body is extremely low, it is not expected to affect your fertility.

Driving and using machines

Your ability to drive and use machines will not be affected by this medicine.

3. How to use Filsuvez

Follow the instructions for administration of this medicine exactly as told by your doctor, pharmacist, or nurse. If you are unsure, talk to your doctor, pharmacist, or nurse again.

Methods of administration

  • Clean the wound before applying Filsuvez.
  • You can apply Filsuvez in two ways:
  1. Apply directly to the wound
    • Apply a thick layer (about 1 mm thick) of Filsuvez to the wound (step 1).
    • Spread the gel generously and cover the entire wound area with a clean hand or glove (step 2). Do notrub the gel.
    • Cover with a non-adhesive sterile dressing (step 3).

Step 1: Apply

Step 2: Spread

Step 3: Cover

Tube squeezing cream onto a white and black intravaginal applicator

Hand applying pressure on a rectangular adhesive dressing placed on the skin

Gauze strips with a grid texture, one partially unfolded showing its length and pattern

Or

  1. Apply to a non-adhesive sterile dressing
    • Apply a thick layer (about 1 mm thick) of Filsuvez to the wound dressing (step 1).
    • Spread generous amounts of gel to the area that will be in direct contact with the wound with a clean hand or glove (step 2).
      • Cover the wound with the dressing (step 3).

Step 1: Apply

Step 2: Spread

Step 3: Cover

Hand applying cream or ointment to a grid-textured surface with white lines and dark background

Hand applying a rectangular medicinal patch to the arm skin with firm pressure

Hand slowly peeling off the protective transparent cover of a medicinal adhesive patch on a grid background

  • Reapply the gel every time the dressing is changed, until the wound is healed.
  • Filsuvez is not intendedfor internal use. Avoid contact with the eyes, mouth, or nostrils. In case of accidental contact, rinse immediately with clean water.
  • This tube of sterile gel is intended for single use. Once opened, the gel must be used immediately and the tube must be discarded, even if some gel remains. A new tube should be used for each dressing change.

Duration of treatment

Your doctor, pharmacist, or nurse will tell you how long you should use the gel. If your symptoms continue or worsen after use, or if complications occur in the wound, talk to your doctor, pharmacist, or nurse.

If you use more Filsuvez than you should

Filsuvez is applied to the skin and absorption into the body is extremely low. This makes overdose very unlikely, even if applied to large areas of skin and for a long period of time.

If you forget to use Filsuvez

Apply Filsuvez at the next scheduled dressing change, continuing with your usual routine.

If you stop using Filsuvez

Filsuvez should be used as directed by your doctor, pharmacist, or nurse. Do not stop using itwithout talking to your doctor, pharmacist, or nurse.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor, pharmacist, or nurse immediately if you notice any of the following side effects, including those listed below.

Very common(may affect more than 1 in 10 people)

  • wound complications (e.g., increased wound size, wound reopening, and pain in the wound)

Common(may affect up to 1 in 10 people)

  • wound infection
  • allergic reaction (hypersensitivity)
  • itching of the skin
  • pain and itching at the application site
  • wound healing complications

Uncommon(may affect up to 1 in 100 people)

  • wound secretion
  • skin irritation (dermatitis)
  • itchy rash
  • purple-colored rash
  • pain

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible that they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Filsuvez

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and tube after "EXP". The expiry date is the last day of the month shown.

Store below 30°C.

This tube of sterile gel is intended for single use. Once opened, the gel must be used immediately and the tube must be discarded, even if some gel remains. A new tube should be used for each dressing change.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

Composition of Filsuvez

The active substance is dry extract of birch bark.

1 g of gel contains: 100 mg of extract (as refined dry extract) from Betula pendulaRoth, Betula pubescensEhrh., as well as hybrids of both species, bark (equivalent to 0.5-1.0 g of birch bark), including 84-95 mg of triterpenes calculated as the sum of betulin, betulinic acid, erythrodiol, lupeol, and oleanolic acid. Extraction solvent: n-heptane.

The other ingredient is refined sunflower oil.

Appearance of the product and pack contents

Filsuvez is a colorless to slightly yellowish, opalescent, and non-aqueous gel.

Filsuvez gel is available in white, foldable aluminum tubes. The tubes are closed with a tamper-evident aluminum membrane and are equipped with a white polypropylene screw cap.

The tube is packaged in a cardboard box.

Pack sizes:

1 tube, 10 tubes, and 30 tubes of 23.4 g gel.

Not all pack sizes may be marketed.

Marketing authorisation holder and manufacturer

Chiesi Farmaceutici S.p.A.

Via Palermo 26/A

43122 Parma

Italy

Manufacturer

Amryt GmbH

Streiflingsweg 11

75223 Niefern-Öschelbronn

Germany

You can request more information about this medicine from the local representative of the marketing authorisation holder:

België/Belgique/Belgien

Chiesi sa/nv

Tel: + 32 (0)2 788 42 00

Lietuva

ExCEEd Orphan s.r.o.

Bucharova 2657/12, Prague 5, 158 00

Czech Republic

Tel.: +370 661 663 99

pv.global@exceedorphan.com

Text with contact information of a Bulgarian company ExCEEd Orphan sro, address in Prague, and phone and email data

Luxembourg/Luxemburg

Chiesi sa/nv

Tel: + 32 (0)2 788 42 00

Ceská republika

ExCEEd Orphan s.r.o.

Bucharova 2657/12, Prague 5, 158 00

Czech Republic

Tel: +420 724 321 774

pv.global@exceedorphan.com

Magyarország

ExCEEd Orphan s.r.o.

Bucharova 2657/12, Prague 5, 158 00

Czech Republic

Tel.: +36 20 399 4269

pv.global@exceedorphan.com

Danmark

Chiesi Pharma AB

Tlf: + 46 8 753 35 20

Malta

Amryt Pharmaceuticals DAC

Tel: +44 1604 549952

medinfo@amrytpharma.com

Deutschland

Chiesi GmbH

Tel: + 49 40 89724-0

Nederland

Chiesi Pharmaceuticals B.V.

Tel: + 31 88 501 64 00

Eesti

ExCEEd Orphan s.r.o.

Bucharova 2657/12, Prague 5, 158 00

Czech Republic

Tel.: +370 661 663 99

pv.global@exceedorphan.com

Norge

Chiesi Pharma AB

Tlf: + 46 8 753 35 20

Ελλάδα

Amryt Pharmaceuticals DAC

Τηλ: +800 44 474447

Τηλ: +44 1604 549952

medinfo@amrytpharma.com

Österreich

Chiesi Pharmaceuticals GmbH

Tel: + 43 1 4073919

España

Chiesi España, S.A.U.

Tel: + 34 93 494 8000

Polska

ExCEEd Orphan s.r.o.

Bucharova 2657/12, Prague 5, 158 00

Czech Republic

Tel: +48 502 188 023

pv.global@exceedorphan.com

France

Chiesi S.A.S.

Tél: + 33 1 47688899

Portugal

Chiesi Farmaceutici S.p.A.

Tel: + 39 0521 2791

Hrvatska

ExCEEd Orphan Distribution d.o.o.

Savska cesta 32, Zagreb, 100 00

Croatia

Tel: +385 99 320 0330

pv.global@exceedorphan.com

România

ExCEEd Orphan s.r.o.

Bucharova 2657/12, Prague 5, 158 00

Czech Republic

Tel: +40 744 366 015

pv.global@exceedorphan.com

Ireland

Chiesi Farmaceutici S.p.A.

Tel: + 39 0521 2791

Slovenija

ExCEEd Orphan s.r.o.

Bucharova 2657/12, Prague 5, 158 00

Czech Republic

Tel: +386 30 210 050

pv.global@exceedorphan.com

Ísland

Chiesi Pharma AB

Sími: +46 8 753 35 20

Slovenská republika

ExCEEd Orphan s.r.o.

Bucharova 2657/12, Prague 5, 158 00

Czech Republic

Tel: +420 608 076 274

pv.global@exceedorphan.com

Italia

Chiesi Italia S.p.A.

Tel: + 39 0521 2791

Suomi/Finland

Chiesi Pharma AB

Puh/Tel: +46 8 753 35 20

Κύπρος

Amryt Pharmaceuticals DAC

Τηλ: +800 44 474447

Τηλ: +44 1604 549952

medinfo@amrytpharma.com

Sverige

Chiesi Pharma AB

Tel: +46 8 753 35 20

Latvija

ExCEEd Orphan s.r.o.

Bucharova 2657/12, Prague 5, 158 00

Czech Republic

Tel.: +370 661 663 99

pv.global@exceedorphan.com

Date of last revision of this leaflet:

Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu, and on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (https://www.aemps.gob.es/). There are also links to other websites about rare diseases and orphan medicines.

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Follow us on social media
FacebookInstagram
Logo
Oladoctor
Find a doctor
Doctors by specialty
Services
Choose language
© 2025 Oladoctor. All rights reserved.
VisaMastercardStripe